Effect of  MAF  amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial

Robert Coleman; Andrew Hall; Joan Albanell; Andrew Hanby; Richard Bell; David Cameron; David Dodwell; Helen Marshall; Joël Jean-mairet; Juan-carlos Tercero; Federico Rojo; Walter Gregory; Roger R Gomis

doi:10.1016/S1470-2045(17)30603-4

Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial

Robert Coleman, Andrew Hall, Joan Albanell, Andrew Hanby, Richard Bell, David Cameron, David Dodwell, Helen Marshall, Joël Jean-mairet, Juan-carlos Tercero, Federico Rojo, Walter Gregory, Roger R Gomis

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	The Lancet Oncology
DOIs	https://doi.org/10.1016/S1470-2045(17)30603-4
Publication status	Published - 13 Oct 2017

Access to Document

10.1016/S1470-2045(17)30603-4

THELANCETONCOLOGY-D-17-00548R4
This is a pre-copyedited, author-produced version of an article accepted for publication in The Lancet Oncology following peer review. The version of record " Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial" is available online at: http://dx.doi.org/10.1016/S1470-2045(17)30603-4
Accepted author manuscript, 652 KB

http://linkinghub.elsevier.com/retrieve/pii/S1470204517306034

Cite this

Coleman, R., Hall, A., Albanell, J., Hanby, A., Bell, R., Cameron, D., Dodwell, D., Marshall, H., Jean-mairet, J., Tercero, J., Rojo, F., Gregory, W., & Gomis, R. R. (2017). Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial. The Lancet Oncology. https://doi.org/10.1016/S1470-2045(17)30603-4

@article{b4f8577fb24f449c89a34e68fe7fb0ff,

title = "Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial",

author = "Robert Coleman and Andrew Hall and Joan Albanell and Andrew Hanby and Richard Bell and David Cameron and David Dodwell and Helen Marshall and Jo{\"e}l Jean-mairet and Juan-carlos Tercero and Federico Rojo and Walter Gregory and Gomis, {Roger R}",

year = "2017",

month = oct,

day = "13",

doi = "10.1016/S1470-2045(17)30603-4",

language = "English",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

}

Coleman, R, Hall, A, Albanell, J, Hanby, A, Bell, R, Cameron, D, Dodwell, D, Marshall, H, Jean-mairet, J, Tercero, J, Rojo, F, Gregory, W & Gomis, RR 2017, 'Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial', The Lancet Oncology. https://doi.org/10.1016/S1470-2045(17)30603-4

Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial. / Coleman, Robert; Hall, Andrew; Albanell, Joan et al.
In: The Lancet Oncology, 13.10.2017.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial

AU - Coleman, Robert

AU - Hall, Andrew

AU - Albanell, Joan

AU - Hanby, Andrew

AU - Bell, Richard

AU - Cameron, David

AU - Dodwell, David

AU - Marshall, Helen

AU - Jean-mairet, Joël

AU - Tercero, Juan-carlos

AU - Rojo, Federico

AU - Gregory, Walter

AU - Gomis, Roger R

PY - 2017/10/13

Y1 - 2017/10/13

U2 - 10.1016/S1470-2045(17)30603-4

DO - 10.1016/S1470-2045(17)30603-4

M3 - Article

SN - 1470-2045

JO - The Lancet Oncology

JF - The Lancet Oncology

ER -